Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.65 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18448102 | 0.83 | PTGS2 (0.72) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL4291816 | 0.81 | PTGS1 (0.69) | PTGS2PTGS1NR3C2CYP2C9 | |
| SCHEMBL14747588 | 0.79 | PTGS2 (0.63) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL4538661 | 0.79 | NR3C2 (0.65) | PTGS2PTGS1NR3C2 | |
| Mavacoxib SCHEMBL212699 | 0.79 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL3246379 | 0.79 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL4587051 | 0.78 | PTGS2 (0.73) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL8265772 | 0.78 | PTGS2 (0.73) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL8917353 | 0.78 | PTGS2 (0.68) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL15347126 | 0.78 | PTGS2 (0.68) | PTGS2PTGS1NR3C2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1971596-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | Takeda Pharmaceutical Company Limited (JP) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007077961-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | PTGS2 697/4885PTGS1 437/4885NR3C2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.